Greenall SA - Search Results

1

A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors.

Endersby R, Whitehouse J, Hii H, Greenall SA, Johns TG, Gottardo NG. Endersby R, et al. Among authors: greenall sa. Neoplasia. 2018 May;20(5):432-442. doi: 10.1016/j.neo.2018.02.004. Epub 2018 Mar 22. Neoplasia. 2018. PMID: 29574250 Free PMC article.

2

Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo.

Greenall SA, Donoghue JF, Gottardo NG, Johns TG, Adams TE. Greenall SA, et al. Oncogene. 2015 Mar 26;34(13):1658-66. doi: 10.1038/onc.2014.106. Epub 2014 Apr 21. Oncogene. 2015. PMID: 24747966

3

Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.

Greenall SA, Gherardi E, Liu Z, Donoghue JF, Vitali AA, Li Q, Murphy R, Iamele L, Scott AM, Johns TG. Greenall SA, et al. PLoS One. 2012;7(4):e34658. doi: 10.1371/journal.pone.0034658. Epub 2012 Apr 12. PLoS One. 2012. PMID: 22511956 Free PMC article.

4

Incomplete target neutralization by the anti-cancer antibody rilotumumab.

Greenall SA, Adams TE, Johns TG. Greenall SA, et al. MAbs. 2016;8(2):246-52. doi: 10.1080/19420862.2015.1122149. MAbs. 2016. PMID: 26750997 Free PMC article.

5

Differential Sensitivity of Human Hepatocellular Carcinoma Xenografts to an IGF-II Neutralizing Antibody May Involve Activated STAT3.

Greenall SA, Donoghue J, Johns TG, Adams TE. Greenall SA, et al. Transl Oncol. 2018 Aug;11(4):971-978. doi: 10.1016/j.tranon.2018.05.011. Epub 2018 Jun 22. Transl Oncol. 2018. PMID: 29933129 Free PMC article.

6

Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response.

Donoghue JF, Kerr LT, Alexander NW, Greenall SA, Longano AB, Gottardo NG, Wang R, Tabar V, Adams TE, Mischel PS, Johns TG. Donoghue JF, et al. Among authors: greenall sa. Cancers (Basel). 2018 Jul 25;10(8):243. doi: 10.3390/cancers10080243. Cancers (Basel). 2018. PMID: 30044378 Free PMC article.

7

Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma.

Greenall SA, McKenzie M, Seminova E, Dolezal O, Pearce L, Bentley J, Kuchibhotla M, Chen SC, McDonald KL, Kornblum HI, Endersby R, Adams TE, Johns TG. Greenall SA, et al. Neuro Oncol. 2019 Aug 5;21(8):1016-1027. doi: 10.1093/neuonc/noz073. Neuro Oncol. 2019. PMID: 31002307 Free PMC article.

8

Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth.

Nilsson UW, Johns TG, Wilmann T, Kaitu'u-Lino T, Whitehead C, Dimitriadis E, Menkhorst E, Saglam B, Gao Y, Greenall SA, Horne AW, Tong S. Nilsson UW, et al. Among authors: greenall sa. Obstet Gynecol. 2013 Oct;122(4):737-744. doi: 10.1097/AOG.0b013e3182a1ba56. Obstet Gynecol. 2013. PMID: 24084529

9

EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications.

Greenall SA, Donoghue JF, Van Sinderen M, Dubljevic V, Budiman S, Devlin M, Street I, Adams TE, Johns TG. Greenall SA, et al. Oncogene. 2015 Oct 8;34(41):5277-87. doi: 10.1038/onc.2014.448. Epub 2015 Feb 9. Oncogene. 2015. PMID: 25659577

10

EGFRvIII: the promiscuous mutation.

Greenall SA, Johns TG. Greenall SA, et al. Cell Death Discov. 2016 Jul 4;2:16049. doi: 10.1038/cddiscovery.2016.49. eCollection 2016. Cell Death Discov. 2016. PMID: 27551537 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters